Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection

Binding of antibodies to oligomeric envelope glycoprotein of R5-tropic primary isolates of human immunodeficiency virus type 1 (HIV-1) was studied by flow cytometry using sera from HIV-1 vaccine recipients and clade B and C HIV-1-infected patients, and monoclonal and polyclonal antibodies to neutral...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2004-01, Vol.22 (3), p.383-397
Main Authors: Gorse, Geoffrey J, Patel, Gira B, Arbuckle, J.Alan, Belshe, Robert B
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
AIDS
AIDS Vaccines - immunology
Animals
Antibodies
Antibodies, Monoclonal - immunology
Biological and medical sciences
Canarypox virus
Canarypox virus - immunology
Epitopes - immunology
Flow Cytometry
Fluorescent Antibody Technique
Fundamental and applied biological sciences. Psychology
Gene Products, env - metabolism
glycoprotein gp120
Goats - immunology
HIV
HIV Antibodies - analysis
HIV Antibodies - metabolism
HIV Envelope Protein gp120 - immunology
HIV Envelope Protein gp160 - metabolism
HIV Infections - immunology
HIV-1
Human immunodeficiency virus
Human immunodeficiency virus 1
Human viral diseases
Humans
Immunization
Infectious diseases
Lymphocytes
Lymphocytes - immunology
Medical sciences
Microbiology
Protein Binding
Recombinant Proteins - metabolism
Vaccine
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Vaccines, Synthetic - immunology
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Binding of antibodies to oligomeric envelope glycoprotein of R5-tropic primary isolates of human immunodeficiency virus type 1 (HIV-1) was studied by flow cytometry using sera from HIV-1 vaccine recipients and clade B and C HIV-1-infected patients, and monoclonal and polyclonal antibodies to neutralizing epitopes of HIV-1. Vaccine recipients received recombinant canarypox virus vaccine expressing HIV-1 gene products, and SF-2 recombinant gp120 subunit vaccine. Anti-gp120 neutralizing antibodies including human monoclonal antibody 2G12 and goat polyclonal anti-serum to V3 loop peptide [peptide T1-SP10MN(A)] bound to HIV-1-infected cells. Sera from vaccine recipients bound to HIV-1-infected cells, but at levels lower than did infected patient sera.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2003.07.013